Pharmacokinetics—the study of drug absorption, distribution, metabolism, and excretion (ADME)—determines virtually every practical aspect of therapeutic agent use: route of administration, dosing frequency, drug interactions, inter-individual variability, and safety margin. For peptide therapeutics, ADME properties present both unique challenges and exploitable opportunities distinguishing this drug class from small molecules and larger biologics.
The Oral Bioavailability Barrier
Developing orally bioavailable peptide drugs has represented pharmaceutical science's longstanding challenge—combining molecular specificity of biologics with administration convenience of small molecules. Native peptide oral bioavailability typically ranges below 5%, often closer to 1%, rendering oral routes impractical for most applications.
Multiple conspire against intestinal peptide absorption:
Enzymatic degradation: GI lumen contains proteases (pepsin at gastric pH, trypsin/chymotrypsin/elastase in small intestine) evolved specifically to hydrolyze dietary proteins into absorbable amino acids and di/tripeptides. Therapeutic peptides represent substrates regardless of sequence sophistication.
Size exclusion: Intestinal epithelium permits passive diffusion only for small (<500 Da), lipophilic molecules. Most therapeutic peptides vastly exceed paracellular pore size limits (~3.4-8 Å radius) and lack sufficient lipophilicity for transcellular passage.
First-pass metabolism: Any fraction surviving intestinal encounter faces hepatic extraction before reaching systemic circulation—further reducing already-minimal bioavailability.
Subcutaneous Administration: The Clinical Workhorse
Subcutaneous injection into adipose tissue dominates peptide therapeutics administration—offering practical compromise among bioavailability (~50-80% vs IV), patient acceptability, and pharmacokinetic control. Understanding SC absorption physiology enables rational protocol optimization.
Absorption mechanism: Following deposition, peptide molecules diffuse through extracellular matrix until reaching capillary endothelium, entering systemic circulation via paracellular or transcellular routes. Absorption rate varies by: local blood flow (faster in well-perfused regions), molecular size (smaller = faster), formulation characteristics, and injection site (abdominal > arm > thigh > buttock for most peptides).
| Parameter | Typical Range | Clinical Implication |
|---|---|---|
| Tmax (peak time) | 1-4 hours post-injection | Plan timing relative to meals/activity |
| Half-life (native) | Minutes to few hours | Requires frequent dosing or modification |
| Bioavailability | 50-80% (vs IV reference) | Acceptable for most applications |
| Variability | 30-50% CV between individuals | Necessitates individualized titration |
Half-Life Extension Technologies
Native peptides face rapid renal filtration (below ~60 kDa threshold) and ubiquitous proteolytic degradation limiting duration of action to minutes or few hours. Half-life extension technologies address these limitations through creative chemical engineering:
Pegylation: Covalent polyethylene glycol chain attachment increases hydrodynamic radius (reducing renal filtration), shields protease cleavage sites, and decreases immunogenicity. Trade-offs include potential receptor affinity loss (steric interference) and rare anti-PEG antibody development.
Fatty acid acylation: Attachment of lipid side chains (as in semaglutide's C18 diacid) enables reversible albumin binding—effectively "hitching a ride" on abundant serum protein (19-day half-life) for intermediate duration extension enabling once-weekly dosing.
Drug Affinity Complex (DAC): Used in CJC-1295 DAC variant, this technology binds peptide to albumin-binding moiety producing sustained release over days rather than minutes characterizing native sequence pharmacokinetics.
Drug Interaction Considerations
Peptide-drug interactions occur through several mechanisms requiring prescriber awareness:
- CYP450 pathway: Most peptides avoid hepatic metabolism via cytochrome system (unlike small molecules), reducing classic CYP-mediated interaction potential—but exceptions exist for specific sequences
- Renal excretion competition: Peptides cleared renally may interact with other actively secreted drugs competing for organic anion/cation transporters
- Pharmacodynamic interactions: Additive/synergistic or antagonistic effects at receptor or pathway level (e.g., GLP-1RA + insulin → hypoglycemia risk; GHS + corticosteroids → complex endocrine effects)
- Gastrointestinal effects: Delayed gastric emptying from GLP-1RAs affects absorption timing of concomitant oral medications—practical consideration for drugs requiring specific administration conditions